Metropolis Healthcare launches HPV DNA test to Enhance Cervical Cancer Screening in India

By: WE staff | Monday, 3 February 2025

• Metropolis Healthcare Limited has partnered with Roche Diagnostics India and Neighboring Markets.
• The collaboration introduces a self-sampling HPV DNA test for cervical cancer screening.

On Monday, Metropolis Healthcare Limited announced its collaboration with Roche Diagnostics India and neighboring Markets to launch a self-sampling HPV DNA test for enhanced cervical cancer screening.

The launch of the HPV DNA test aims to expand access to cervical cancer screening across India. This initiative addresses social and economic barriers, making early detection more accessible for women in Tier 2, Tier 3, and Tier 4 towns.

Cervical cancer continues to be a significant health challenge for women in India, despite being preventable through early screening and vaccination. India accounts for 21% of the world’s cervical cancer cases, with nearly 79,000 deaths annually, representing around two-thirds of all diagnosed cases.

The HPV DNA test, endorsed by WHO, detects 14 high-risk HPV types and is FDA-approved and WHO-prequalified. It enables early detection and intervention for cervical cancer.

Metropolis Healthcare, in partnership with Roche Diagnostics India, aims to expand access to screening across India.The self-sampling test allows women to collect samples easily, overcoming barriers like stigma and limited healthcare access.

Only 1.9% of Indian women are screened for cervical cancer, indicating a need for wider access. This test helps reduce discomfort and embarrassment, making screening more accessible in underserved areas.